What's the consensus timeframe for when these will start to hit the market?
I don't think there is consensus. Enbrel is the first one off patent in late 2012 I believe. It really depends on what final biosimilar pathway will be.
RIGL not only needs to worry about anti-TNF biologic, but also PFE's oral Tasocitinib.
Why wouldn't AZN run a head-to-head study to try to differentiate FosD from patients who have yet to try anti-TNF therapy?
Anti-TNF drugs are highly effective drugs. Going head to head against them is extremely risky move. Drug companies don't do that often until after the drugs are established already.
Market Data 
Markets 
AI
